Stifel analyst Thomas Shrader reiterated a Buy rating and $83 price target on Kite Pharma (NASDAQ: KITE) following Q4 results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE